Please ensure Javascript is enabled for purposes of website accessibility

Pfizer and BioNTech Post Positive Trial Data for Their COVID-19 Vaccine

By Brian Orelli, PhD - Updated Jul 1, 2020 at 8:35PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Patients developed antibodies to the coronavirus in the phase 1 clinical trial, but the vaccine also produced side effects.

In an early-stage phase 1/2 clinical trial, BNT162b1, the COVID-19 vaccine being developed by Pfizer (PFE 0.91%) and BioNTech (BNTX -0.87%), produced antibodies against SARS-CoV-2, the novel coronavirus that causes COVID-19, after two doses.

Seven days after the second dose at the lowest two doses, 10 micrograms and 30 micrograms, 12 patients per group had antibodies capable of binding to the novel coronavirus that were 8 and 46.3 times higher, respectively, than the antibody levels of patients who had recovered from COVID-19.

More importantly, the antibodies were also able to keep the virus from infecting cells. The level of so-called neutralizing antibodies were 1.8- and 2.8-times higher than recovered patients at the 10-microgram and 30-microgram doses, respectively.

The drugmakers also tested a 100-microgram dose, but the higher dose produced unwanted side effects, so the patients weren't given a second booster shot.

Syringe drawing medicine from a vial

Image source: Getty Images.

Pfizer and BioNTech are testing four different vaccine candidates in the phase 1/2 clinical trial and plan to take the best candidate into a much larger 30,000-patient phase 2b/3 clinical trial starting as early as later this month. The companies are trailing Moderna, which is finishing up a phase 2 clinical trial for its COVID-19 vaccine, mRNA-1273, with plans to start a phase 3 study next month. But Pfizer and BioNTech's plan to run a combined phase 2b/3 clinical trial could help the duo catch up a little. 

The two companies are gearing up for production of the vaccine, with plans to manufacture up to 100 million doses by the end of this year and potentially more than 1.2 billion doses by the end of 2021.

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$49.02 (0.91%) $0.44
BioNTech SE Stock Quote
BioNTech SE
BNTX
$146.32 (-0.87%) $-1.28

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
397%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.